NCT07892027
Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Start date changed from estimate of Nov 1, 2026 to Nov 10, 2026
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Occurrence of chimeric antigen receptor therapy (CAR-T)-associated neurotoxicity (immune effector cell associated neurotoxicity syndrome [ICANS])
Timeframe: Up to CAR-T day +28
Secondary (5)
Occurrence of severe CAR-T-associated neurotoxicity (ICANS of grade 3 or greater)
Occurrence of severe cytokine release syndrome (cytokine release syndrome [CRS] of grade 3 or greater)
Occurrence of adverse events related to natalizumab
Occurrence of complete response or partial response
Occurrence of serious adverse events related to natalizumab
Arms and interventions
Supportive care (SOC conditioning & CAR-T, natalizumab)Experimental
Patients receive SOC conditioning therapy consisting of fludarabine IV and cyclophosphamide IV on days -4 and -3. Patients then receive natalizumab IV over 1 hour on day -1, followed by SOC CAR T-cell therapy with axicabtagene ciloleucel or brexucabtagene autoleucel on day 0. Patients also undergo PET/CT and blood sample collection throughout the study.
Biologicals: Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, Natalizumab
Procedures: Biospecimen Collection, Computed Tomography, Positron Emission Tomography
Drugs: Cyclophosphamide, Fludarabine
Sites
1 site in 1 country
- University of Michigan Rogel Cancer CenterAnn Arbor, Michigan, United States